In the context of breast cancer, it is noteworthy that serum levels of IL-6 and sIL-6R and their local production in BM by OBs depend on sex steroids, which change with the menstrual cycle, and are negatively regulated by estrogen and hormone replacement therapy and increase up to tenfold during menopause48,62,63. Here, IL6R is linked to breast carcinoma.